Sarina Stephens
Nurse Practitioner · Dothan, ALNPI 1497338388
Payments from drug & device makers
Across 333 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$986
- Novo Nordisk$817
- AstraZeneca$602
- AbbVie$578
- GSK$402
- Pfizer$301
- plus $2K from 26 others
What the payments were for
- Food & beverage$5,374100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 76 | $986 |
| Novo Nordisk | 58 | $817 |
| AstraZeneca | 30 | $602 |
| AbbVie | 32 | $578 |
| GSK | 22 | $402 |
| Pfizer | 18 | $301 |
| Boehringer Ingelheim | 13 | $215 |
| Amgen | 12 | $197 |
| Merck | 9 | $125 |
| Exact Sciences | 6 | $108 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $107 |
| Axsome Therapeutics, Inc. | 4 | $101 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $81 |
| Amarin Pharma, Inc. | 4 | $75 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $67 |
| Kowa Pharmaceuticals America, Inc. | 4 | $67 |
| Phathom Pharmaceuticals, Inc. | 4 | $61 |
| Corcept Therapeutics | 3 | $58 |
| Johnson & Johnson | 3 | $55 |
| Abbott | 3 | $53 |
| E.r. Squibb & Sons, L.L.C. | 3 | $48 |
| Dexcom, Inc. | 2 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Almatica Pharma LLC | 2 | $30 |
| Eisai Inc. | 2 | $29 |
| Corium, LLC | 1 | $25 |
| Bayer | 1 | $20 |
| Impel Pharmaceuticals Inc. | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $18 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $17 |
| Genentech USA, Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$117
How this compares
$5,374 in reported general payments places this provider in the 90th percentile of 1,505 nurse practitioner providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 112 | $138,734 |
| JardianceEmpagliflozin | 102 | $128,790 |
| EliquisApixaban | 76 | $85,043 |
| OzempicSemaglutide | 64 | $70,180 |
| TrulicityDulaglutide | 65 | $65,731 |
| JanuviaSitagliptin Phosphate | 49 | $51,692 |
| FarxigaDapagliflozin Propanediol | 41 | $46,676 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $40,612 |
| MyrbetriqMirabegron | 26 | $21,677 |
| XareltoRivaroxaban | 18 | $21,194 |
| LinzessLinaclotide | 18 | $16,052 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $10,043 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $7,383 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 18 | $5,626 |
| DuleraMometasone/Formoterol | 14 | $5,304 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30 | $986 | $206,527193 claims |
| Boehringer IngelheimJardiance | $215 | $128,790102 claims |
| PfizerEliquis | $301 | $85,04376 claims |
| Novo NordiskOzempic | $817 | $70,18064 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $402 | $58,03883 claims |
| MerckJanuvia, Dulera | $125 | $56,99663 claims |
| AstraZenecaFarxiga | $602 | $46,67641 claims |
| Johnson & JohnsonXarelto | $55 | $21,19418 claims |
| AbbVieLinzess | $578 | $16,05218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,505 nurse practitioner providers in Alabama.
Other nurse practitioner in Dothan
- Hollie CrutchfieldDothan$22K
- Christina BellDothan$14K
- Shea CalhounDothan$14K
- Amanda PybusDothan$13K
- Tami CaldwellDothan$13K
- Alison HallDothan$12K
- Jennifer ParrishDothan$12K
- Amanda SewellDothan$11K
- Amy EthridgeDothan$11K
- Allison McAllisterDothan$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.